Release Date: April 30, 2025
Expiration Date: April 30, 2026
Activity Overview
Breast cancer is the most common cancer in women of childbearing age. Historically, the gonadotoxic effects of chemotherapy and the prolonged use of endocrine therapy in women with hormone receptor positive (HR+) breast cancer posed significant barriers to future fertility, leaving patients with limited options and difficult choices. However, recent advances in reproductive medicine and a deeper understanding of cancer biology have led to the development of effective fertility preservation strategies-such as oocyte and embryo cryopreservation, and ovarian suppression with gonadotropin-releasing hormone agonists-that are now transforming the outlook for young women with HR+ breast cancer who wish to preserve their reproductive potential without compromising cancer outcomes.
This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the 42nd Annual Miami Breast Cancer Conference, held in March 2025. This unique and engaging multi-media activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with breast cancer, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
Target Audience
This educational activity is directed toward medical oncologists, oncology nurses, advanced practice providers, pharmacists, and other health care professionals involved in the care of premenopausal patients with metastatic HR+ breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Discuss current strategies for fertility preservation, including ovarian function suppression (OFS) with gonadotropin-releasing hormone (GnRH) agonists, embryo/oocyte cryopreservation, and combinational approaches.
- Review current and emerging clinical data on the efficacy and safety of GnRH agonists for ovarian suppression and fertility preservation while treating premenopausal women with hormone receptor-positive (HR+) breast cancer.
- Integrate recent guidelines and individual patient factors to determine adequate OFS strategies for management of premenopausal patients with HR+ advanced breast cancer.
- Determine strategies to optimize outcomes, including adverse event management, in patients receiving GnRH agonists for treatment of HR+ breast cancer.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
